Selpercatinib
CAS: 2152628-33-4
Ref. 3D-CLD62833
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued |
Product Information
Selpercatinib is a small molecule drug that inhibits the activity of tyrosine kinases, which are enzymes that play an important role in cell growth and differentiation. Selpercatinib has been shown to inhibit a number of tyrosine kinases, including RET, VEGFR-2, KIT and PDGFR-b. Selpercatinib is currently being investigated for the treatment of colorectal adenocarcinoma and hepatic impairment. Selpercatinib has also been shown to be effective against solid tumours in vitro. The drug exhibits high affinity against x-ray crystal structures of RET and VEGFR-2 kinase domains. Selpercatinib has a low molecular weight and is soluble in water at low concentrations, making it easily solubilized in aqueous buffer solutions or cell culture media. In vitro assays have been conducted to determine selpercatinib’s long term efficacy
